About UCSF Search UCSF UCSF Medical Center

I. Craig Henderson, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Adjunct Professor, Department of Medicine (Hematology/Oncology), UCSF

chenderson@hendersonmd.org

Phone: (415) 674-5148 (voice)
Box 1710, UCSF
San Francisco, CA 94143-1710

View on UCSF Profiles


Education

Grinnell College, Grinnell, IA, A.B., 1963
Columbia University, College of Physicians & Surgeons, New York, NY, M.D., 1970


Professional Experience

  • 1970-1972
    Intern and Resident in Medicine, Presbyterian Hospital, New York, NY
  • 1972-1974
    Research Associate, Viral Leukemia and Lymphoma Branch, NCI, Bethesda
  • 1974-1975
    Clinical Fellow in Medicine, Sydney Farber Cancer Inst., Harvard Medical School (HMS)
  • 1975-1976
    Instructor of Medicine, Sydney Farber Cancer Inst., HMS
  • 1976-1984
    Assistant Professor of Medicine, Dana-Farber Cancer Inst., HMS
  • 1979-1992
    Founder and Director, Breast Evaluation Center, Dana-Farber Cancer Inst., Boston
  • 1981-1982
    Consultant, Cancer Unit, World Health Organization, Geneva, Switzerland
  • 1982-1996
    Breast Core Committee, Cancer and Acute Leukemia Group B (Chairman 1990-1995)
  • 1983-1993
    Subcommittee on Antineoplastic and Immunosuppressive Drugs, Committee on Essential Drugs, World Health Organization (Chairman 1983)
  • 1984-1992
    Associate Professor of Medicine, Dana-Farber Cancer Inst., HMS, Boston
  • 1985-1993
    World Health Organization Expert Advisory Panel on Cancer, Geneva
  • 1985-1995
    Early Breast Cancer Trialists Collaborative Group (Oxford Overview Group) (Chairman 1985-1995)
  • 1987-1990
    United States Congressional Office of Technology Assessment: Working Group on Immuno-Augmentative Therapy
  • 1988-1994
    National Task Force on Breast Cancer Control, American Cancer Society
  • 1989-1992
    Member, Oncologic Drugs Advisory Committee, FDA (Chairman 1990-1992)
  • 1991-1993
    Education Committee, American Society of Clinical Oncology
  • 1992-1995
    Professor of Medicine, University of California San Francisco (UCSF)
  • 1992-1995
    Chief, Division of Oncology, Moffitt-Long-Mt. Zion
  • 1992-1995
    Assoc. Director for Clinical Oncology in Comprehensive Cancer Center, UCSF (Interim)
  • 1992-1996
    Founder, PI, Bay Area Breast Cancer Translational Research Program (NIH Specialized Program of Research Excellence, SPORE)
  • 1996-present
    Steering Committee Member, Bay Area Breast Cancer Translational Research Program (NIH Specialized Program of Research Excellence, SPORE)
  • 1995-present
    Adjunct Professor of Medicine, University of California San Francisco
  • 1995-1999
    CEO and Chairman, SEQUUS Pharmaceuticals, Menlo Park Ca.
  • 1999-present
    Senior Consultant, Alza Corporation, Mountain View, Ca. (Director 1999-2001)
  • 2000-present
    Institute of Medicine Committee on Technologies for the Early Detection of Breast Cancer (Vice Chairman)
  • 2000-present
    Breast Cancer Research Council of the State of California
  • 2001-present
    President and Director, Access Oncology, Inc., New York City, NY

Honors & Awards

  • 1966
    Merck, Sharpe and Dohme International Fellow, Columbia University
  • 1970
    Research Prize, Columbia University Medical Society
  • 1988
    Fellow, American College of Physicians
  • 1987
    Henrietta Banting Memorial Lecturer, Canada
  • 1992
    General Motors Cancer Research Foundation Lecturer, The Royal Marsden
  • 1992
    Bernard L. Schwartz Lecturer, Scripps Memorial Hospitals
  • 1993
    British Oncological Association Lecturer, United Kingdom
  • 1993
    Distinguished Alumnus Award, Grinnell College
  • 1994
    Doctorate of Science, Grinnell College
  • 1996
    Wendell Scott Lecture, American College of Radiology
  • 1997
    Fellow, Royal College of Physicians (Edinburgh)
  • 1999
    Outstanding Industry Leader in Medical Research, California Pacific Medical Center Research Institute
  • 2000
    Millennium Award from Bristol-Myers Squibb Oncology and Susan G. Komen Breast Cancer Foundation

Selected Publications

  1. Henderson IC. Can we abandon anthracyclines for early breast cancer patients? Oncology (Williston Park). 2011 Feb; 25(2):115-24, 127.
    View on PubMed
  2. Henderson IC. Adjuvant chemotherapy is not for everyone. Breast Cancer Res Treat. 2010 Aug; 123(1):159-62.
    View on PubMed

Go to UCSF Profiles, powered by CTSI